$599
Basal Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i

New Empa + BI 690517 Ph2 CKD Data; Madrigal and Vertex Q3 ‘23 Earnings; MannKind Completes INHALE-3 Enrollment; November CHMP Agenda

A series of cardiometabolic-related news items have been observed from Boehringer Ingelheim, Madrigal, Vertex, MannKind, and EMA. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home